TDMS Study 05040-02 Pathology Tables
INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)
HYDROQUINONE
NTP Experiment-Test: 05040-02 Report: PEIRPT05
Study Type: CHRONIC Date: 09/05/94
Route: GAVAGE Time: 11:58:40
Facility: American Biogenics Corp.
Chemical CAS #: 000123319
Lock Date: None
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05040-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC HYDROQUINONE Date: 09/05/94
Route: GAVAGE Time: 11:58:40
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE VEHICLE 50 MG/KG 100MG/KG
CONTROL
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 65 65 65
Scheduled Sacrifice 10 10 10
Early Deaths
Moribund 7 11 6
Dead 11 5 9
Accident 4
Survivors
Terminal Sacrifice 37 39 36
Animals Examined Microscopically 55 55 55
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (50) (12) (48)
Intestine Large, Cecum (52) (13) (53)
Intestine Large, Colon (52) (14) (52)
Intestine Small, Duodenum (52) (15) (51)
Serosa, Fibrosarcoma, Metastatic, Mesentery 1 (7%)
Intestine Small, Ileum (49) (14) (52)
Intestine Small, Jejunum (52) (12) (52)
Liver (55) (55) (55)
Cholangiocarcinoma, Metastatic 1 (2%)
Hemangioma 1 (2%) 1 (2%)
Hemangiosarcoma 1 (2%)
Hepatocellular Carcinoma 1 (2%) 2 (4%) 2 (4%)
Hepatocellular Adenoma 2 (4%) 11 (20%) 11 (20%)
Hepatocellular Adenoma, Multiple 4 (7%) 1 (2%)
Histiocytic Sarcoma 1 (2%)
Mesentery (19) (12) (4)
Cholangiocarcinoma, Metastatic 1 (8%)
Fibrosarcoma 1 (8%)
Fibrosarcoma, Multiple 1 (8%)
Pancreas (54) (16) (53)
Fibrosarcoma, Early Invasion, Metastatic,
Mesentery 1 (6%)
Salivary Glands (54) (54) (54)
Histiocytic Sarcoma 1 (2%)
Stomach (54) (17) (55)
Stomach, Forestomach (54) (17) (55)
Squamous Cell Papilloma 1 (6%)
Stomach, Glandular (53) (16) (55)
____________________________________________________________________________________________________________________________________
Page 2
NTP Experiment-Test: 05040-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC HYDROQUINONE Date: 09/05/94
Route: GAVAGE Time: 11:58:40
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE VEHICLE 50 MG/KG 100MG/KG
CONTROL
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (55) (17) (55)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland (55) (13) (55)
Capsule, Cholangiocarcinoma, Metastatic 1 (8%)
Adrenal Gland, Cortex (55) (13) (55)
Adrenal Gland, Medulla (51) (11) (52)
Pheochromocytoma Malignant 1 (2%)
Pheochromocytoma Benign 1 (2%)
Islets, Pancreatic (51) (15) (52)
Pituitary Gland (52) (29) (52)
Pars Distalis, Adenoma 11 (21%) 14 (48%) 11 (21%)
Pars Distalis, Carcinoma 1 (2%) 2 (7%)
Pars Intermedia, Adenoma 1 (2%) 1 (2%)
Thyroid Gland (55) (55) (55)
Follicular Cell, Adenoma 3 (5%) 5 (9%) 6 (11%)
Follicular Cell, Carcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Tissue NOS (1) (1)
Sarcoma, Poorly Differentiated 1 (100%)
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (55) (53) (54)
Adenoma 1 (2%)
Cystadenoma 1 (2%)
Osteosarcoma, Metastatic, Bone 1 (2%)
Teratoma 1 (2%)
Uterus (54) (29) (55)
Hemangioma 1 (3%)
Polyp Stromal 1 (3%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (55) (16) (54)
Lymph Node (55) (22) (54)
Lumbar, Osteosarcoma, Metastatic, Bone 1 (5%)
Pancreatic, Histiocytic Sarcoma 1 (2%)
Lymph Node, Mandibular (50) (16) (49)
Page 3
NTP Experiment-Test: 05040-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC HYDROQUINONE Date: 09/05/94
Route: GAVAGE Time: 11:58:40
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE VEHICLE 50 MG/KG 100MG/KG
CONTROL
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - cont
Histiocytic Sarcoma 1 (2%)
Lymph Node, Mesenteric (52) (17) (52)
Histiocytic Sarcoma 1 (2%)
Renal, Cholangiocarcinoma, Metastatic 1 (6%)
Spleen (55) (22) (55)
Capsule, Cholangiocarcinoma, Metastatic 1 (5%)
Thymus (44) (13) (47)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (52) (20) (53)
Adenocarcinoma 3 (6%) 5 (25%) 2 (4%)
Cholangiocarcinoma, Multiple, Metastatic 1 (5%)
Thoracic, Hepatocellular Carcinoma,
Metastatic, Liver 1 (5%)
Skin (55) (16) (55)
Basal Cell Carcinoma 1 (2%)
Subcutaneous Tissue, Fibrosarcoma 1 (2%) 1 (6%)
Subcutaneous Tissue, Hepatocellular
Carcinoma, Metastatic, Liver 1 (6%)
Tail, Neurofibrosarcoma 1 (2%)
Thoracic, Subcutaneous Tissue,
Hemangiosarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (55) (16) (55)
Lumbar, Vertebra, Osteosarcoma 1 (6%)
Vertebra, Cholangiocarcinoma, Metastatic 1 (6%)
Skeletal Muscle (2) (1)
Abdominal, Fibrosarcoma, Early Invasion,
Metastatic, Mesentery 1 (50%)
Abdominal, Diaphragm, Cholangiocarcinoma,
Metastatic 1 (50%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (55) (16) (55)
Carcinoma, Extension, Metastatic, Pituitary
Gland 1 (2%) 1 (6%)
Cerebrum, Oligodendroglioma Malignant 1 (2%)
____________________________________________________________________________________________________________________________________
Page 4
NTP Experiment-Test: 05040-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC HYDROQUINONE Date: 09/05/94
Route: GAVAGE Time: 11:58:40
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE VEHICLE 50 MG/KG 100MG/KG
CONTROL
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (55) (55) (55)
Alveolar/Bronchiolar Adenoma 3 (5%) 6 (11%) 1 (2%)
Alveolar/Bronchiolar Adenoma, Multiple 1 (2%)
Alveolar/Bronchiolar Carcinoma 1 (2%) 2 (4%)
Basal Cell Carcinoma, Metastatic 1 (2%)
Carcinoma, Metastatic 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Osteosarcoma, Metastatic, Bone 1 (2%)
Trachea (54) (16) (55)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Ear (1)
Canal, External Ear, Squamous Cell Carcinoma 1 (100%)
Harderian Gland (3) (3) (7)
Adenoma 2 (67%) 2 (67%) 2 (29%)
Carcinoma 2 (29%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (55) (16) (55)
Hepatocellular Carcinoma, Metastatic 1 (6%)
Osteosarcoma, Metastatic, Bone 1 (6%)
Capsule, Cholangiocarcinoma, Metastatic 1 (6%)
Renal Tubule, Adenoma 1 (2%) 1 (2%)
Urinary Bladder (53) (15) (54)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(55) *(55) *(55)
Histiocytic Sarcoma 1 (2%)
Lymphoma Malignant 3 (5%) 1 (2%) 3 (5%)
Lymphoma Malignant Histiocytic 1 (2%) 1 (2%)
Lymphoma Malignant Lymphocytic 14 (25%) 7 (13%) 9 (16%)
Lymphoma Malignant Mixed 7 (13%) 5 (9%) 6 (11%)
Lymphoma Malignant Undifferentiated Cell 1 (2%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 5
NTP Experiment-Test: 05040-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC HYDROQUINONE Date: 09/05/94
Route: GAVAGE Time: 11:58:40
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE VEHICLE 50 MG/KG 100MG/KG
CONTROL
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 43 42 39
Total Primary Neoplasms 64 76 67
Total Animals with Benign Neoplasms 21 33 27
Total Benign Neoplasms 26 47 36
Total Animals with Malignant Neoplasms 31 21 27
Total Malignant Neoplasms 38 29 31
Total Animals with Metastatic Neoplasms 2 4 1
Total Metastatic Neoplasm 2 21 1
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 6
NTP Experiment-Test: 05040-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC HYDROQUINONE Date: 09/05/94
Route: GAVAGE Time: 11:58:40
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE VEHICLE 50 MG/KG 100MG/KG
CONTROL
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 65 65 65
Scheduled Sacrifice 10 10 10
Early Deaths
Moribund 12 10 5
Dead 10 7 14
Survivors
Terminal Sacrifice 33 37 36
Wrong Sex 1
Animals Examined Microscopically 55 54 55
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (44) (11) (48)
Intestine Large, Cecum (49) (13) (49)
Intestine Large, Colon (49) (14) (48)
Intestine Large, Rectum (50) (15) (52)
Serosa, Carcinoid Tumor Benign 1 (2%)
Intestine Small, Ileum (48) (10) (47)
Adenocarcinoma 1 (2%)
Intestine Small, Jejunum (50) (13) (45)
Liver (55) (54) (55)
Fibrosarcoma, Metastatic, Skin 1 (2%)
Hemangioma 1 (2%)
Hemangioma, Marked 1 (2%)
Hemangiosarcoma 1 (2%) 1 (2%) 2 (4%)
Hepatocellular Carcinoma 12 (22%) 11 (20%) 7 (13%)
Hepatocellular Carcinoma, Multiple 1 (2%)
Hepatocellular Adenoma 9 (16%) 15 (28%) 15 (27%)
Hepatocellular Adenoma, Multiple 6 (11%) 5 (9%)
Sinusoid, Sarcoma 1 (2%)
Mesentery (6) (4) (5)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (17%)
Pancreas (54) (15) (53)
Salivary Glands (55) (16) (55)
Stomach, Forestomach (55) (15) (53)
Squamous Cell Papilloma 2 (4%)
____________________________________________________________________________________________________________________________________
Page 7
NTP Experiment-Test: 05040-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC HYDROQUINONE Date: 09/05/94
Route: GAVAGE Time: 11:58:40
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE VEHICLE 50 MG/KG 100MG/KG
CONTROL
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (55) (17) (55)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland (55) (53) (54)
Adrenal Gland, Cortex (55) (52) (54)
Adenoma 2 (4%) 2 (4%)
Adrenal Gland, Medulla (54) (52) (54)
Pheochromocytoma Benign 1 (2%) 3 (6%)
Pituitary Gland (50) (14) (50)
Pars Distalis, Adenoma 3 (6%)
Thyroid Gland (55) (53) (54)
Follicular Cell, Adenoma 2 (4%) 1 (2%) 2 (4%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Tissue NOS (1) (1)
Carcinoma 1 (100%)
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (54) (17) (54)
Prostate (55) (17) (55)
Seminal Vesicle (55) (17) (55)
Testes (55) (18) (55)
Interstitial Cell, Adenoma 1 (2%) 3 (5%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Lymph Node (55) (29) (55)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Lymph Node, Mandibular (52) (17) (51)
Lymph Node, Mesenteric (54) (23) (50)
Spleen (55) (52) (54)
Thymus (39) (10) (42)
____________________________________________________________________________________________________________________________________
Page 8
NTP Experiment-Test: 05040-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC HYDROQUINONE Date: 09/05/94
Route: GAVAGE Time: 11:58:40
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE VEHICLE 50 MG/KG 100MG/KG
CONTROL
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (55) (33) (55)
Fibroma 1 (2%) 1 (3%)
Fibrosarcoma 2 (4%) 1 (3%) 1 (2%)
Squamous Cell Papilloma 1 (2%)
Subcutaneous Tissue, Fibroma 1 (2%) 1 (3%)
Subcutaneous Tissue, Fibroma, Multiple 1 (3%)
Subcutaneous Tissue, Fibrosarcoma 5 (9%) 8 (24%) 2 (4%)
Subcutaneous Tissue, Hemangiosarcoma 1 (2%)
Subcutaneous Tissue, Neurofibroma 1 (2%)
Subcutaneous Tissue, Sarcoma 1 (2%) 3 (9%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (54) (32) (55)
Osteosarcoma 1 (2%)
Skeletal Muscle (3)
Intercostal, Alveolar/Bronchiolar Carcinoma,
Metastatic, Lung 1 (33%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (55) (17) (55)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (55) (31) (55)
Alveolar/Bronchiolar Adenoma 5 (9%) 9 (29%) 3 (5%)
Alveolar/Bronchiolar Adenoma, Multiple 1 (2%) 1 (2%)
Alveolar/Bronchiolar Carcinoma 8 (15%) 4 (13%) 6 (11%)
Hepatocellular Carcinoma, Metastatic, Liver 5 (9%) 3 (5%)
Nose (55) (17) (55)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Ear (1)
Pinna, Histiocytic Sarcoma 1 (100%)
Harderian Gland (5) (2) (7)
Adenoma 5 (100%) 2 (100%) 6 (86%)
____________________________________________________________________________________________________________________________________
Page 9
NTP Experiment-Test: 05040-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC HYDROQUINONE Date: 09/05/94
Route: GAVAGE Time: 11:58:40
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE VEHICLE 50 MG/KG 100MG/KG
CONTROL
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (55) (17) (55)
Renal Tubule, Carcinoma 1 (2%)
Urinary Bladder (54) (15) (55)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(55) *(54) *(55)
Histiocytic Sarcoma 1 (2%)
Lymphoma Malignant Histiocytic 2 (4%) 2 (4%)
Lymphoma Malignant Lymphocytic 4 (7%) 9 (17%) 4 (7%)
Lymphoma Malignant Mixed 2 (4%) 1 (2%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 10
NTP Experiment-Test: 05040-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC HYDROQUINONE Date: 09/05/94
Route: GAVAGE Time: 11:58:40
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE VEHICLE 50 MG/KG 100MG/KG
CONTROL
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 39 46 44
Total Primary Neoplasms 79 84 69
Total Animals with Benign Neoplasms 23 31 29
Total Benign Neoplasms 38 41 41
Total Animals with Malignant Neoplasms 30 34 23
Total Malignant Neoplasms 41 43 28
Total Animals with Metastatic Neoplasms 7 4
Total Metastatic Neoplasm 9 4
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 11
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------
--multipart-boundary
Content-type: text/plain
Range: bytes 65389-65389/65389
--multipart-boundary--